Management of Pain Flashcards

1
Q

TYPES OF PAIN?

A
  • Nociceptive
  • Inflammatory
  • Neuropathic
  • Functional
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is NOCICEPTIVE PAIN?

A

• Nociceptive pain is pain in response to a
noxious stimulus.
• Can be either somatic or visceral.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is INFLAMMATORY PAIN?

A

• When tissue damage occurs despite the
nociceptive defense system, inflammatory pain
ensues.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is Neuropathic pain?

A

• Neuropathic pain results from damage to or

dysfunction of the peripheral or central nervous system, rather than stimulation of pain receptors.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is functional pain?

A

• Functional pain is pain sensitivity due to an
abnormal processing or function of the central
nervous system in response to normal stimuli.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Define acute pain?

A

• Pain that occurs as a result of injury or surgery and is
usually self-limited, subsiding when the injury heals.
• Usually nociceptive, although it can be neuropathic.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Define chronic pain?

A

• Under normal conditions, acute pain subsides quickly.
However, in some instances pain persists for months to
years, leading to chronic pain.
• Chronic pain may be nociceptive, inflammatory,
neuropathic, or functional.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Differentiate chronic malignant and chronic non-malignant pain?

A

CHRONIC MALIGNANT PAIN
• Chronic malignant pain is associated with a
progressive disease like cancer or AIDS.

CHRONIC NON-MALIGNANT PAIN
• Pain not associated with a life-threatening disease and lasting longer than 6 months beyond the healing period.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Guidelines by the WHO for treatment of cancer pain?

A

• For mild pain (1–3/10), management should be
started at step 1.
• For mild to moderate pain (4–6/10), it should be
started at step 2.
• For moderate to severe pain (7–10/10), it should
be started at step 3.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Outline of how to treat mild, moderate, and severe pain?

A

• Mild pain is generally treated with nonopioid
analgesics.
• Mild to Moderate pain is treated with
combinations of medium-potency opioids +/-
nonopioid analgesics.
• Moderate to severe pain is treated with high
potency opioids +/- nonopioid analgesics .
• Adjuvant medications are added as needed to
manage adverse effects and/or to augment
analgesia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Which two drugs can be used for mild to moderate and added benefit?
Chronic pain?

A

• Acetaminophen and NSAIDs are often effective
for mild to moderate pain.
• Nonopioids do not cause physical dependence
or tolerance.
OPIOID ANALGESICS
• Agents of choice for the management of
moderate to severe acute and chronic pain.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Acetaminophen and NSAID’s role in the management of pain?

A

ACETAMINOPHEN
• Often selected as initial therapy for mild to
moderate pain.
• First-line for low back pain and osteoarthritis.
• Hepatotoxicity has been reported with excessive
use and overdose.
NSAIDs
• Used for the treatment of mild to moderate pain,
especially the pain of inflammation such as that
of arthritis and gout.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

4 drugs for mild to moderate pain?

A
  • NSAIDs
  • Acetaminophen
  • Codeine
  • Tramadol
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Drugs used for moderate to severe pain?

A
  • Morphine (DOC in severe pain)
  • Hydromorphone
  • Oxymorphone
  • Meperidine
  • Fentanyl
  • Levorphanol
  • Methadone
  • Oxycodone
  • Hydrocodone
  • Pentazocine (3rd line)
  • Butorphanol (2nd line)
  • Nalbuphine (2nd line)
  • Buprenorphine (2nd line)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Describe Analgesic dosing?

A

• Analgesics should be given orally and by the
clock, ie at fixed intervals of time.
• The dose should be gradually increased until the
patient is comfortable.
• The next dose should be given before the effect
of the previous one has fully worn off.
• As the pain subsides, as-needed schedules
may be appropriate.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Define breakthrough pain?

Treatment for breakthrough pain?

A

• Transitory severe acute pain that occurs on a
background of chronic pain that is adequately
controlled by an opioid regimen.

• Rescue doses are given for relief.
• Typically, a short-acting supplemental opioid is
used.
• A typical rescue dose is 5 to 15 % of the basal
daily requirement of opioid.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Breakthrough pain formulations?

A
• Breakthrough pain may be targeted with a transmucosal fentanyl formulation.
• Six formulations are available in the US:
• Oral transmucosal lozenge
• Immediate-release transmucosal tablet
• Effervescent buccal tablet
• Buccal soluble film
• Nasal spray
• Sublingual spray
• Fentanyl oral
transmucosal lozenge.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

THE ANALGESIC CEILING EFFECT define?

A

• The analgesic ceiling effect of a drug refers to
the dose beyond which there is no additional
analgesic effect.
• Higher doses do not provide any additional pain
relief but may increase the likelihood of side
effects.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Analgesic ceiling effect with opiods and non-opioids?

A

• Nonopioids have an analgesic ceiling.
• Pure opioid agonists have no analgesic ceiling.
• When using a combination of an opioid with an
nonopioid, the analgesic ceiling of the nonopioid
should be the dose-limiting factor.
• Mixed agonist-antagonists, such as pentazocine,
butorphanol, nalbuphine, and buprenorphine, do
have a ceiling effect.
• They are poor choices for patients with severe
pain.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

ROA for opiods?

A
  • Opioids may be administered in a variety of routes:
  • Oral (tablet and liquid)
  • Sublingual
  • Rectal
  • Transdermal
  • Transmucosal
  • Intravenous
  • Subcutaneous
  • Intraspinal
21
Q

ROA benefits of PCA?

A

• PCA allows patients to self-administer parenteral
analgesics.
• The patient depresses a button to activate the
PCA controller to deliver a preset dose of opiate
medication
• Patient-controlled IV delivery of opioids has
often been considered the gold standard for
management of acute postoperative pain.
• Opioids used in PCA devices include morphine,
hydromorphone, fentanyl, and methadone.

22
Q

NOT RECOMMENDED ANALGESICS

FOR ROUTINE DOSING opiod agonist?

A
MEPERIDINE
• Meperidine has a half-life of 3 h.
• Its principal metabolite, normeperidine, has a
half-life of 15-20 h.
• Normeperidine produces significant adverse
effects when it accumulates:
• Dysphoria
• Myoclonus
• Seizures
23
Q

Not recommended anaglesic for routine dosing mixed agonist-antagonist?

A

MIXED AGONIST-ANTAGONISTS
• Mixed agonist-antagonists are not recommended as routine analgesics, as their
dosing is limited by a ceiling effect.
• Additionally, pentazocine, nalbuphine and
butorphanol cause psychotomimetic adverse
effects.
• Mixed agonist-antagonists should not be used in
a patient already taking a pure agonist opioid.
• Competition for the opioid receptors may cause
a withdrawal reaction.

24
Q

why do COMBINATION THERAPY?

A

• The combination of opioid and nonopioid
analgesics often results in analgesia superior to
that produced by either agent alone.

25
Q

Common adverse effects of opioids?

A
  • Pruritus
  • Constipation
  • Nausea/Vomiting
  • Sedation
26
Q

Managing pruritus as opioid ae? Nausea /vomitting?

A

Pruritus
• Due to histamine release from mast cells.
• Can be managed with hydroxyzine or
diphenhydramine.

Nausea/vomiting
• Usually disappears as tolerance develops
within a few days.
• It can be treated with hydroxyzine,
metoclopramide or prochlorperazine
27
Q

Managing constipation in opioid?

A

Constipation
• Almost universal.
• Tolerance to constipation may develop very
slowly, if at all.
• A laxative should be prescribed when opioid is
started.
• Usually a stimulant laxative is prescribed.
• A combination stimulant/softener can be useful.
• Bulk-forming agents require substantial fluid
intake and are not recommended for patients
with advanced disease and poor mobility.

28
Q

MANAGING OPIOID sedation Ae?

A

Sedation
• Usually disappears over a few days as tolerance develops.
• Persistent opioid-induced sedation that limits
activity can be managed with methylphenidate
or modafinil.

29
Q

Management of respiratory depression with opioids?

A

Respiratory depression
• Many physicians have an exaggerated view of
the risk of respiratory depression when using
opioids to relieve pain.
• Tolerance to respiratory depression
develops quickly.
• If respirations are compromised, naloxone may
be necessary.

30
Q

what are ANALGESIC ADJUNCTIVE AGENTS

(COANALGESICS)?

A

• Adjuvant analgesics are drugs which are useful
in the management of pain but that are not
primarily classified as analgesics.
• They can be used as monotherapy or in
combination with non-opioids and opioids.

31
Q

List coanalgesics?

A
  • ANTIDEPRESSANTS
  • ANTICONVULSANTS
  • GLUCOCORTICOIDS
  • OTHER DRUGS
32
Q

What are 2 mainstay of treatment for several neuropathic pain
syndromes?

A

ANTIDEPRESSANTS AND ANTICONVULSANTS

33
Q

What are NEUROPATHIC PAIN: MAIN CAUSES

A
  • Diabetic peripheral neuropathy
  • Postherpetic neuralgia
  • Cancer
  • Spinal cord injury
  • Multiple sclerosis
  • Trigeminal neuralgia
34
Q

moa of antidepressant action in adjuvant of pain?

A

• Serotonin and norepinephrine mediate
descending inhibition of ascending pain pathways in
the brain and spinal cord.
• Antidepressants that enhance both serotonergic
and noradrenergic transmission display significant analgesic effects.
• Drugs with these actions are:
• Tricyclic antidepressants (TCAs)
• Serotonin and norepinephrine reuptake
inhibitors (SNRIs).
TCAs and SNRIs cause
analgesia by inhibiting
norepinephrine and serotonin reuptake.
• Antidepressant agents that enhance only
serotonergic transmission, such as the selective
serotonin reuptake inhibitors (SSRIs) are less
effective.

35
Q

• TCAs commonly used as analgesics are:

A
  • Amitriptyline
  • Imipramine
  • Desipramine
  • Nortriptyline
36
Q

Tricyclic antidepressants AE?

A

• Most common adverse effects: constipation, dry
mouth, blurred vision, cognitive changes,
tachycardia, urinary hesitation.
• Associated with their anticholinergic activity.
• Other common adverse effects: sexual
dysfunction, orthostatic hypotension, weight
gain, sedation.
• Secondary amines (desipramine, nortriptyline)
exhibit fewer anticholinergic and sedative effects
than do the tertiary amines (amitriptyline,
imipramine).
• Secondary amines are more desirable in the
elderly population.

37
Q

TCAs should be administered cautiously in

patients with:

A
  • Angle-closure glaucoma
  • BPH
  • Urinary retention
  • Constipation
  • CV disease
  • Impaired liver function.
38
Q

• TCAs should be avoided in patients with:

A
  • Second- or third-degree heart block
  • Arrhythmias
  • Prolonged QT interval
  • Severe liver disease
  • Recent acute MI.
39
Q
SEROTONIN & NOREPINEPHRINE
REUPTAKE INHIBITORS (SNRIs) pain use and differences from TCAs?
A

• SNRIs selectively inhibit reuptake of serotonin and
norepinephrine.
• SNRIs lack the antihistamine, α-adrenergic blocking, and anticholinergic effects of TCAs.
• Venlafaxine and duloxetine are effective for
several types of neuropathic pain

40
Q

SNRIs: ADVERSE EFFECTS?

A
  • Nausea, sexual dysfunction, somnolence.

* SNRIs are better tolerated than TCAs.

41
Q

ANTICONVULSANTS used for management of pain?

A
  • Useful in the management of neuropathic pain.
  • Gabapentin & Pregabalin
  • Carbamazepine & Oxcarbazepine
42
Q

moa and ae of Gabapentin and pregabalin?

A

MECHANISM OF ACTION
• Block voltage-gated calcium-channels. This
decreases release of glutamate, norepinephrine,
and substance P.
ADVERSE EFFECTS
• Dizziness, somnolence, peripheral edema.

43
Q

CARBAMAZEPINE & OXCARBAZEPINE uses?

A

• Carbamazepine is the DOC for treatment of pain
due to trigeminal neuralgia.
• Oxcarbazepine is also effective and better
tolerated.
• Trigeminal neuralgia is different from other types of
neuropathic pain and responds to different
pharmacologic agents

44
Q

CARBAMAZEPINE & OXCARBAZEPINE moa?

A

MECHANISM OF ACTION
• Voltage-gated sodium channels in sensory neurons
play a crucial role in neuropathic pain.
• Carbamazepine & oxcarbazepine block voltage gated sodium channels

45
Q

AE of CARBAMAZEPINE & OXCARBAZEPINE

A

ADVERSE EFFECTS
• Drowsiness, dizziness, nausea and vomiting.
• Carbamazepine-induced leukopenia is not
uncommon, but it is usually benign.
• Aplastic anemia is a rare side effect.
• Oxcarbazepine is better tolerated.

46
Q

Topical Therapies used for pain?

A

Lidocaine Patches
• Used for localized peripheral neuropathic pain
(particularly postherpetic neuralgia).
Capsaicin Patches
• Capsaicin depletes substance P from the terminals of afferent C fibers. A high-concentration capsaicin patch is approved for postherpetic neuralgia.
Clonidine
• Can be administered orally, transdermally, or intraspinally. May improve pain in sympathetically maintained pain.

47
Q

Glucocorticoids role in pain management?

A

• Commonly used in advanced illness.
• Useful for acute nerve compression, increased
intracranial pressure, bone pain, visceral pain,anorexia, nausea, and depressed mood.
• Dexamethasone is the DOC.
• Prednisone and methylprednisolone can also be used.
• Glucocorticoids have several other indications.
• They can improve appetite, nausea, malaise,
and overall quality of life.

48
Q

Bisphosphonates role in pain management?

A

• Bisphosphonates have analgesic effects on pain
of bony origin.
• Efficacious particularly with bone metastasis and
multiple myeloma.
• The bisphosphonates that have shown efficacy
in malignant bone pain conditions are zoledronate and pamidronate.
• Zoledronate is the most commonly used